An open-label study of the clinical and biologic responses to MabThera [rituximab] in patients with chronic lymphocytic leukemia responsive to first-line treatment with chlorambucil and prednisone
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2010
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 09 Jun 2006 New trial record.